Xilio Therapeutics (XLO) Price & Analysis

Compare

208 Followers

XLO Stock Chart & Stats

$0.81

-$0.02(-1.59%)

At close: Jan 08 4:00 PM EST

$0.81

-$0.02(-1.59%)

Day’s Range― - ―

52-Week Range$0.62 - $1.70

Previous CloseN/A

Volume162.24K

Average Volume (3M)763.65K

Market Cap

$41.56M

Enterprise Value-$48.41M

Total Cash (Recent Filing)$121.55M

Total Debt (Recent Filing)$7.57M

Price to Earnings (P/E)―

Beta-0.05

Next Earnings

Mar 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding51,830,450

10 Day Avg. Volume402,315

30 Day Avg. Volume763,649

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)2.90

Price to Sales (P/S)8.06

P/FCF Ratio-2.78

Enterprise Value/Market Cap-1.16

Enterprise Value/Revenue-3.23

Enterprise Value/Gross Profit-3.23

Enterprise Value/Ebitda0.88

Forecast

1Y Price Target

$2.00

Price Target Upside146.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical SuccessVilastobart is positioned for development and commercial success in the relapsed/refractory and earlier-line colorectal cancer settings.

Financial StabilityThe company ended the quarter with $121.6M in cash and cash equivalents, which should sustain operations into 3Q26.

Strategic PartnershipsXilio plans to use these emerging datasets to identify a partner to push vilastobart further into clinical development.

Bears Say

Financial LossXilio reported a Q2 net loss of $15.8MM and cash of $121.6MM, which includes proceeds from a follow-on offering closed in June.

Partnership UrgencyFinding the right partner quickly is critical for both the asset and the company.

Xilio Therapeutics News

Xilio Therapeutics presents new data across portfolio at SITC

Xilio Therapeutics (XLO) announced new data across its portfolio, including preclinical data highlighting the potential for Xilio’s masked...

2d ago

XLO

Xilio Therapeutics announces new data on Phase 2 trial of vilastobart

Xilio Therapeutics (XLO) announced new data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced...

2d ago

XLO

Xilio Therapeutics Transfers Listing to Nasdaq Capital Market

Xilio Therapeutics ( ($XLO) ) just unveiled an update. On October 2, 2025, Xilio Therapeutics received approval from...

1M ago

XLO

Xilio Therapeutics Initiates Phase 2 Trial for XTX301

Xilio Therapeutics ( ($XLO) ) has issued an announcement. On September 9, 2025, Xilio Therapeutics announced the initiation...

2M ago

XLO

Xilio Therapeutics announces initiation of Phase 2 trial for efarindodekin alfa

Xilio Therapeutics (XLO) announced the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical...

2M ago

XLO

GILD

Xilio Therapeutics sees cash runway into 1Q27

As of June 30, 2025, Xilio had cash and cash equivalents of $121.6M. Based on its current operating...

2M ago

XLO

Xilio Therapeutics Faces Nasdaq Equity Compliance Challenge

Xilio Therapeutics ( ($XLO) ) has shared an update. On August 22, 2025, Xilio Therapeutics, Inc. received a...

2M ago

XLO

Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results

Xilio Therapeutics Inc ( ($XLO) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

XLO

Promising Future for Xilio Therapeutics: Strong Financial Position and Encouraging Trial Results Support Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on XLO stock, giving a Buy rating on...

3M ago

XLO

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

Reports Q2 revenue $8.084M vs $2.357M last year. “During the second quarter, we continued to make strong progress...

3M ago

XLO

Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

ALC

Xilio Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Xilio Therapeutics (XLO) with an Outperform rating and $72 price target The company’s lead...

3M ago

XLO

Xilio Therapeutics Expands Authorized Shares at Annual Meeting

Xilio Therapeutics ( ($XLO) ) has issued an announcement. On June 10, 2025, Xilio Therapeutics held its annual...

5M ago

XLO

Xilio Therapeutics Expands Board with New Director

Xilio Therapeutics ( ($XLO) ) has provided an announcement. On June 10, 2025, Xilio Therapeutics expanded its Board...

5M ago

XLO

XLO FAQ

What was Xilio Therapeutics’s price range in the past 12 months?

Xilio Therapeutics lowest stock price was $0.61 and its highest was $1.70 in the past 12 months.

What is Xilio Therapeutics’s market cap?

Xilio Therapeutics’s market cap is $41.56M.

When is Xilio Therapeutics’s upcoming earnings report date?

Xilio Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 115 days.

How were Xilio Therapeutics’s earnings last quarter?

Currently, no data Available

Is Xilio Therapeutics overvalued?

According to Wall Street analysts Xilio Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xilio Therapeutics pay dividends?

Xilio Therapeutics does not currently pay dividends.

What is Xilio Therapeutics’s EPS estimate?

Xilio Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Xilio Therapeutics have?

Xilio Therapeutics has 51,830,450 shares outstanding.

What happened to Xilio Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Xilio Therapeutics?

Currently, no hedge funds are holding shares in XLO

Xilio Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-277.74%

Trailing 12-Months

Asset Growth

48.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xilio Therapeutics

Xilio Therapeutics (XLO) is a biotechnology company focused on developing tumor-selective immuno-oncology therapies. It operates within the healthcare and biotechnology sectors, with a core emphasis on engineering therapies that localize their activity within tumors to minimize systemic toxicity. The company's proprietary technology platform is designed to enhance the therapeutic index of its drugs, aiming to offer more effective and safer cancer treatments.

Xilio Therapeutics (XLO) Earnings & Revenues

Historic Earnings Reports

XLO Stock 12 Month Forecast

Average Price Target

$2.00

▲(146.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.7538461538461538,0.8576923076923078,0.9615384615384616,1.0653846153846154,1.1692307692307693,1.273076923076923,1.376923076923077,1.4807692307692308,1.5846153846153848,1.6884615384615387,1.7923076923076926,1.896153846153846,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.7538461538461538,0.8576923076923078,0.9615384615384616,1.0653846153846154,1.1692307692307693,1.273076923076923,1.376923076923077,1.4807692307692308,1.5846153846153848,1.6884615384615387,1.7923076923076926,1.896153846153846,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.7538461538461538,0.8576923076923078,0.9615384615384616,1.0653846153846154,1.1692307692307693,1.273076923076923,1.376923076923077,1.4807692307692308,1.5846153846153848,1.6884615384615387,1.7923076923076926,1.896153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.7,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >